Genomics-Based Cancer Theranostics

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Scopus citations

Abstract

Cancer cells have advantages over normal cells of selective growth and survival, and genetic mutations are the root of those advantages. Over the past decade, especially since the advent of next generation sequencing (NGS) technologies, also known as second generation, in the mid-2000s, genomic landscapes for the most common forms of human cancer have been revealed, and such discoveries are benefiting early tumor diagnosis, prognosis, and treatments. Today, third generation sequencing platforms are entering the markets and bringing a new wave of discoveries as they allow a much longer sequencing read than the second generation platforms. This chapter reviews the advanced biotechnology and computational biology efforts necessary to make sense of the astronomical amount of cancer genomics data to identify novel biomarkers for developing targeted imaging probes and therapeutics, and clarify the achievements, opportunities, and challenges for genomics-based cancer theranostics.

Original languageEnglish (US)
Title of host publicationCancer Theranostics
PublisherElsevier
Pages9-20
Number of pages12
ISBN (Print)9780124077225
DOIs
StatePublished - Mar 2014

Keywords

  • Bioinformatics
  • Cancer
  • Cancer genome landscapes
  • Driver mutation
  • Drug resistance
  • Heterogeneity
  • High content screening
  • Next generation sequencing
  • Signaling pathways

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'Genomics-Based Cancer Theranostics'. Together they form a unique fingerprint.

Cite this